caa a22 4500 469120916 CHVBK 20180323133138.0 cr unu---uuuuu 170328e19920601xx s 000 0 eng 10.1007/BF02245260 doi (NATIONALLICENCE)springer-10.1007/BF02245260 Effects of oral BMY 21502 on Morris water task performance in 16-18 month old F-344 rats [Elektronische Daten] [Mark Lindner, Valentin Gribkoff] In the present study we have examined the effects of oral administration of BMY 21502, a potential cognition enhancing drug, on the impaired Morris water task performance of 16-18 month old F-344 rats. BMY 21502 did not affect swim speeds or performance on the first trial of each day, but it did increase the rate of acquisition and initial retention, resulting in decreased swim distances on the second trial of each day. This increased rate of acquisition was dose-dependent, increasing to a peak at 5.0 mg/kg; the effect was decreased at 10 mg/kg, but still above control values. These results suggest that BMY 21502 is orally active over a broad range of doses, and lend further support for its potential as a therapeutic agent for the treatment of dementia. Springer-Verlag, 1992 BMY 21502 nationallicence Age nationallicence Learning nationallicence Cognitive dysfunction nationallicence Morris water maze nationallicence Lindner Mark Department of Neuropharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, 06492, Wallingford, CT, USA aut Gribkoff Valentin Department of Neuropharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, 06492, Wallingford, CT, USA aut Psychopharmacology Springer-Verlag 107/4(1992-06-01), 485-488 0033-3158 107:4<485 1992 107 213 https://doi.org/10.1007/BF02245260 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245260 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lindner Mark Department of Neuropharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, 06492, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Gribkoff Valentin Department of Neuropharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, 06492, Wallingford, CT, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 107/4(1992-06-01), 485-488 0033-3158 107:4<485 1992 107 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer